Insertion of a non-biodegradable drug delivery implant — a subcutaneous capsule or pellet placed for long-term, controlled drug release.

Verified May 8, 2026 · 6 sources ↓

Medicare: $107.55
Total RVUs: 3.22
Global, days: 0
Region: General

Drawn from CMSAcogAAOSReproductiveaccess

Documentation requirements

What must appear in the operative or office note to support the claim.

Source · Editorial brief grounded in 6 cited references ↓

Pre-procedure counseling note documenting benefits, risks, and alternatives discussed with the patient, plus signed informed consent
Operative/procedure note specifying insertion site (e.g., medial upper arm), laterality (left or right), anesthesia type and amount used
Implant details: drug name, dosage, manufacturer lot number, and device type (biodegradable vs. non-biodegradable)
Insertion technique documented explicitly, including trocar use, tissue bed preparation, and any closure method applied
Medical necessity diagnosis supporting long-term drug delivery (ICD-10 code matched to payer-approved indications)
Separate supply documentation if billing J7307 or other HCPCS drug code alongside the procedure code

Applicable modifiers

Modifiers commonly billed with this code.

Source · AMA CPT modifier descriptors · CMS NCCI Policy Manual

25 Significant separate E/M 51 Multiple procedures 52 Reduced services 59 Distinct service LT Left side RT Right side 76 Repeat, same physician 77 Repeat, another physician 78 Unplanned return — related 79 Unrelated during global

What this code covers

Source · Editorial summary grounded in 6 cited references ↓

CPT 11981 covers the subcutaneous insertion of a non-biodegradable implant designed to deliver medication over an extended period. The procedure involves surgically defining a placement site, preparing the tissue bed, and accurately positioning the implant — typically a silastic capsule — using a trocar system. The most common clinical applications include etonogestrel contraceptive implants (Nexplanon), hormone pellet therapy, and select other long-acting drug delivery scenarios. Unlike 11980, which covers biodegradable/compounded pellets placed with a needle anywhere in the body, 11981 is specifically for non-biodegradable devices that require precise anatomical placement, usually the subdermal tissue of the upper arm.

The global period is 000, meaning only same-day pre- and post-service work is bundled — nothing carries over. Bill the drug supply separately; J7307 covers the etonogestrel implant system including supplies. The procedure code does not include the cost of the device. If removal with reinsertion is performed at a later date, report 11983 rather than billing 11981 and 11982 together.

Top billing specialties include orthopedic surgery, podiatry, urology, and OB/GYN. Payer coverage policies vary significantly for hormone pellet therapy versus FDA-approved contraceptive implants — confirm medical necessity criteria with each payer before insertion, especially for testosterone or estradiol pellet applications.

RVU & reimbursement

Component RVUs and Medicare national rate. Actual payment varies by GPCI locality.

Source · CMS Physician Fee Schedule, RVU26A · January 2026

Work RVU	1.11
Practice expense RVU	1.9
Malpractice RVU	0.21
Total RVU	3.22
Medicare national rate	$107.55
Global period	0 days

Payment by site of service

Medicare pays different rates by setting. HOPD typically pays substantially more than ASC for the same procedure.

Source · CMS OPPS Addendum B·ASC HCPCS payment rates·2026

Setting	Medicare rate (national)
Office (PFS non-facility) Procedure performed in physician's office	$107.55
HOPD (APC 5734) Hospital outpatient department	$135.93

Common denial reasons

The recurring reasons claims for CPT 11981 get rejected.

Source · Editorial brief grounded in CMS NCCI edits, AAOS coding appeals, and cited references ↓

Billing 11981 and 11982 on the same date without a distinct clinical justification — payers bundle removal and reinsertion under 11983
Missing or mismatched HCPCS drug code (J7307) — procedure code alone does not capture the implant device cost, and some payers deny without the supply code
Diagnosis code not matching payer-specific medical necessity criteria, especially for hormone pellet therapy (testosterone/estradiol) versus FDA-approved contraceptive implants
Insufficient operative documentation — notes stating only 'implant inserted' without site, technique, device details, or lot number trigger medical review
Global period confusion on same-day E/M billing — modifier 25 required if a separately identifiable evaluation and management service is billed on the same date

Frequently asked questions

Source · Generated from the editorial pipeline, verified against 6 cited references ↓

01What is the difference between CPT 11981 and 11980?

11980 covers subcutaneous implantation of biodegradable or compounded pellets placed with a needle and trocar anywhere in the body. 11981 is for non-biodegradable implants — typically a silastic capsule — that require precise anatomical placement, usually in the upper arm. The RUC and CMS treat these as distinct procedures with different work values.

02Can I bill 11981 and 11982 together on the same date?

No. If you're removing and reinserting a non-biodegradable implant in the same session, bill 11983. Billing 11981 and 11982 together for a same-date removal-plus-insertion is a common denial trigger across payers.

03Do I bill the drug implant device separately from 11981?

Yes. CPT 11981 covers only the insertion procedure. The device itself is billed separately — for example, J7307 for the etonogestrel implant system including supplies. Verify HCPCS code applicability by payer and drug type.

04What modifier is needed if I bill an E/M on the same day as 11981?

Use modifier 25 on the E/M code to indicate it was a separately identifiable service beyond the pre-procedure assessment inherent to the insertion. Document what clinical decision-making justified the separate visit.

05Is 11981 covered for hormone pellet therapy under Medicare?

Coverage varies significantly. Medicare and many commercial payers distinguish between FDA-approved devices (e.g., Nexplanon) and compounded hormone pellets. Testosterone and estradiol pellet insertion often faces coverage restrictions or requires prior authorization. Confirm payer-specific medical necessity criteria before the procedure.

06What is the global period for 11981, and what does that mean for post-insertion visits?

The global period is 000 — same-day only. Post-insertion follow-up visits are separately billable. There is no extended global window bundling routine follow-up care, unlike major surgical codes with 90-day globals.

07If the implant is found superficial or malpositioned shortly after insertion and requires removal and reinsertion, how should that be coded?

If the second encounter involves removal and reinsertion, report 11983. If the complication required a return to the procedure room for a related unplanned service, consider modifier 78 on the return procedure. Document the clinical finding (e.g., superficial placement, infection) clearly in the note.

Sources & references

Editorial content was developed using the following public sources. Last verified May 8, 2026.

Mira AI Scribe

Mira's AI scribe captures insertion site with laterality, trocar technique, tissue bed preparation details, implant drug name and lot number, anesthesia type and dose, and closure method directly from dictation. This prevents the most common audit flag on 11981 — operative notes that document the outcome ('implant placed') without the procedural specifics required to defend medical necessity and support the non-biodegradable device distinction over 11980.

See how Mira captures CPT 11981 documentation